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The Development of the Thalassemia Field
Although it is now realized that the thalassemias are the
commonest monogenic diseases in humans, this was not
always the case. The early history of thalassemia is de-
scribed in detail elsewhere (Weatherall and Clegg 2001).
It was ﬁrst recognized as a distinct entity independently
by workers in the United States and Italy in 1925. It
received its name, derived from Greek roots meaning
“sea” and “blood,” in the mistaken belief that it was
restricted to individuals of Mediterranean background.
However it gradually became apparent that it is a disease
of widespread occurrence in populations ranging from
Africa and the Mediterranean region, through the Mid-
dle Eastern and Indian subcontinent, to Southern China
and Southeast Asia. Work in the 1940s, again carried
out independently in the U.S.A. and Italy, showed that
the disease is inherited in a Mendelian recessive fashion.
And, by this time, it was already clear that the thalas-
semias are characterized by a wide range of clinical dis-
ability and that there might be more than one form of
the condition. But, until the 1950s, there was no un-
derstanding of the underlying cause.
During the 1950s, there was rapid progress toward
an understanding of the structure and function of hu-
man hemoglobin. It was found that normal adults have
a major hemoglobin (Hb), called “Hb A,” comprising
about 90% of the total, and a minor component, “Hb
A2,” which accounts for 2%–3%. Themain hemoglobin
in fetal life is Hb F, only traces of which are found in
normal adults. Earlier during development, there are
three different embryonic hemoglobins. All these dif-
ferent hemoglobins were found to be tetramers of two
pairs of unlike globin chains; adult and fetal hemoglo-
bins have a chains combined with b (Hb A, a2b2), d
(Hb A2, a2d2), or g chains (Hb F, a2g2). In embryonic
life, a-like chains, called “z chains,” and b-like chains,
called “ chains,” combine with g or a chains to pro-
duce the different embryonic hemoglobins. The amino
acid sequence of these different globin chains was de-
termined, considerable progress was made toward an
understanding of the three-dimensional structure of he-
moglobin, and its allosteric properties as an oxygen
transporter were explored.
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Following Pauling’s observation that patients with
sickle-cell anemia have an abnormal hemoglobin (Pau-
ling et al. 1949), scientists in many parts of the world
started to analyze the electrophoretic pattern of human
hemoglobins and found many abnormal variants. These
might affect either the a- or b-globin chains; Hb S, for
example, was found to be a b-chain variant. At the same
time, several seminal observations were made that set
the scene for the further understanding of the thalas-
semias. It was found that many patients with thalas-
semia have persistent fetal hemoglobin after birth and
that most carriers have elevated levels of Hb A2. Of
particular importance was the observation that those
who inherit the sickle-cell gene from one parent and
thalassemia from the other have a completely different
pattern of hemoglobin production from those with the
sickle-cell trait; doubly affected persons show a higher
level of Hb S than Hb A, the opposite of the situation
that occurs in the sickle-cell trait. This suggested that
the action of the thalassemia gene might be to reduce
the level of production of b chains of human hemoglo-
bin. At the same time, patients with the clinical picture
of thalassemia were discovered who had abnormal he-
moglobins consisting of only b chains, b4 tetramers, des-
ignated “Hb H.”
These diverse observations were integrated in 1959
to develop a hypothesis about the possible genetic basis
for the thalassemias. It was suggested that those that
interact with b globin variants like Hb S affect the pro-
duction of b chains of hemoglobin, while those that are
associated with b-chain homotetramers might affect the
production of the a chains of hemoglobin. In short,
there might be two main types of thalassemia, a and b
(Ingram and Stretton 1959). And another important
observation was made at about this time. It was found
that the red-cell precursors of patients with b thalas-
semia contain ragged inclusion bodies (Fessas 1963).
Could these be an abnormal and unstable hemoglobin
due to a mutation of the b-globin genes that had hitherto
been overlooked, were they excess a chains that had
accumulated due to defective b-chain production, or
was there an even more subtle defect in the association
of the globin chains in this condition? Clearly, an ap-
proach was needed to try to explain all these disparate
observations and put the ﬁeld on a harder experimental
footing.
In the 1960s, a method was developed for measuring
the in vitro synthesis globin chains in a quantitative
fashion (Clegg et al. 1965; Weatherall et al. 1965). It
was found that both the a and b thalassemias are char-
acterized by imbalanced globin-chain synthesis. In some
forms of b thalassemia, no b globin chains are synthe-
sized, while in others they are produced at a reduced
rate. The excess a chains consequent on defective b-
chain production are highly unstable and rapidly pre-
cipitate to become associated with the red-cell mem-
brane (Bank and Marks 1966). On the other hand, in
the moderately severe forms of a thalassemia—Hb H
disease, for example—the excess b chains form a large
intracellular pool, some of which are available to com-
bine with b chains to form Hb A, while the others form
Hb H (Clegg and Weatherall 1967). In the more-severe
forms of a thalassemia associated with fetal death and
hydrops fetalis, no a chains are produced at all (Weath-
erall et al. 1970). These experiments were extended to
analyze the rates of initiation and elongation of the
globin chains in thalassemic patients. It was found that
both these mechanisms are normal in patients with a
and b thalassemia (Clegg et al. 1968; Weatherall and
Clegg 1969). Thus, it appeared that the most likely
cause of defective a- or b-chain production lay in a
reduced amount of messenger RNA for the affected
chains, at least in the forms of thalassemia that were
studied in this way. Complementary to this work on
globin synthesis, careful studies of the turnover of the
different hemoglobins in patients with thalassemia, com-
pared with a detailed analysis of their distribution to-
gether with that of inclusion bodies in the red cells,
established a better understanding of the pathophy-
siology of the disease (Nathan and Gunn 1966).
Although, until the mid-1970s, it was not possible to
analyze globin genes directly, some progress was made
toward an understanding of what might be happening
at the DNA level. Using either rabbit-reticulocyte-lysate
or mouse-ascites-tumor systems, together with in vitro
globin synthesis, it was found that there is a deﬁciency
of functional b-globin messenger RNA in b-thalassemic
red cells (Benz and Forget 1971; Nienhuis and Anderson
1971). It was also found that some forms of thalassemia
are associated with the production of abnormal hemo-
globins. For example, some patients with the clinical pic-
ture of b thalassemia were found to have an abnormal
hemoglobin, called “Hb Lepore” after the family name
of the ﬁrst patient in whom it was discovered, which
consisted of a chains combined with variant chains that
were part b and part d. It was suggested that the latter
had arisen by abnormal crossing over between the b
and d globin genes, with the production of ineffectively
synthesized db fusion products (Baglioni 1965). And
some patients with a thalassemia were found to have
traces of a slowly migrating hemoglobin that was also
produced at very low levels and, in this case, was found
to consist of a variant a chain that was elongated at its
C terminal end. It was suggested that this resulted from
a mutation in the a-chain termination codon, with read
through of messenger RNA that is not normally trans-
lated (Weatherall and Clegg 1975). This hypothesis was
validated later when it was found that the amino acid
composition of the elongated portion of the a chain was
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completely consistent with the base sequence of the nor-
mally untranslated region of a globin messenger RNA.
Careful genetic studies of the a thalassemias sug-
gested that there might be two main forms, a thalas-
semia and a thalassemia, in which there was a total or
reduced rate of a-chain production, respectively (Poo-
trakul et al. 1967; Na-Nakorn and Wasi 1970). In the
mid-1970s, using cDNA/DNA hybridization, it was
found that, in homozygotes for a thalassemia, the a
globin genes are deleted, the ﬁrst clear demonstration
of a deletion in a human monogenic disease (Ottolenghi
et al. 1974; Taylor et al. 1974). And structural analyses
showed that some patients with b thalassemia—that
is, those who make no b chains whatever—produce full-
length b-globin mRNA (Old et al. 1978); the ﬁrst ex-
ample of a human nonsense mutation was discovered
by a similar approach (Chang and Kan 1979).
By the end of the 1970s, it became possible to clone
and sequence the globin genes; there were few surprises,
and the order that had been predicted by simple family
studies over the previous 20 years proved to be correct.
The application of Southern blotting, together with the
development of the rapid DNA-sequencingmethods, led
to extensive studies of the molecular pathology of the
disease, work that was facilitated by the discovery of
the strong association between different mutations of
the a- and b-globin genes with restriction fragment–
length polymorphisms of the a- and b-globin gene clus-
ters (Orkin et al. 1982; Higgs et al. 1986). It is now
known that there are over 200 different b-globin gene
mutations that underlie b thalassemia and a large num-
ber of different deletions and nondeletional forms of a
thalassemia (Weatherall and Clegg 2001).
These advances in knowledge of the pathophysiology
and molecular pathology of the thalassemias led to con-
siderable progress in their control and management.
Carriers are relatively easy to identify and—using, ﬁrst,
globin-chain synthesis and, later, DNA technology—
screening and prenatal diagnosis programs were estab-
lished in many countries, leading to a dramatic reduc-
tion in the frequency of new births of children with
severe forms of thalassemia in some of the Mediterra-
nean islands and mainland populations and to consid-
erable progress in this direction in a number of other
countries (Weatherall and Clegg 2001). The use of ade-
quate transfusion regimens combinedwith iron-chelation
agents have altered the prognosis for many severely af-
fected b thalassemic patients (Brittenham et al. 1994;
Olivieri et al. 1994), although, because of the cost and
difﬁculties in compliance, many children are still dying
with this condition early in life in the developing coun-
tries. Bone-marrow transplantation has been applied suc-
cessfully in patients with HLA-matching donors (Tho-
mas et al. 1982; Giardini 1997), but attempts to treat
the condition more directly, either by elevating the level
of fetal hemoglobin or by somatic cell gene therapy,
have not yet been successful.
Current and Future Problems for the Control
and Management of the Thalassemias
Phenotype-Genotype Relationships
Although probably more is known about the genetic
basis for the remarkable variation in clinical phenotype
observed in the thalassemias than for any other mono-
genic disease, many problems remain.
In the case of the b thalassemias, the multilayered
complexity of the genetic basis for phenotypic diversity
is best explained in terms of primary, secondary, and
tertiary genetic modiﬁers (Weatherall 2001). The primary
modiﬁers represent the broad diversity of mutations that
affect the b globin genes, ranging from extremely mild
promoter mutations that cause a very slight reduction
in b globin–chain production to the many different mu-
tations that result in the b thalassemias; that is, a com-
plete absence of b-globin product. Compound hetero-
zygosity for these different mutations can provide a very
broad spectrum of clinical phenotypes. The secondary
genetic modiﬁers are those that are involved directly in
modifying the degree of globin-chain imbalance in b
thalassemia. The coinheritance of a thalassemia has this
effect, and, since there are numerous different molecular
forms of a thalassemia of different severity, this inter-
action provides further scope for a wide range of dif-
ferent b thalassemia phenotypes. Similarly, the degree of
globin-chain imbalance can be reduced by the more ef-
fective synthesis of the g chains of fetal hemoglobin after
birth. It is now known that there are several genes in-
volved in modifying the g-chain response, some that are
encoded in the b globin–gene cluster, others that are on
different chromosomes. The tertiary modiﬁers, those that
are not related to globin chain production but that may
have an important effect on the complications of the
disease, include genes involved with iron absorption, bili-
rubin metabolism, bone metabolism, and, probably, sus-
ceptibility to infection.
As in the case of most monogenic diseases, the effect
of the environment has, until recently, been neglected as
a potential phenotypic modiﬁer. However, ongoing stud-
ies in Sri Lanka suggest that malaria may play an im-
portant role, an observation that, if conﬁrmed, is of con-
siderable importance in light of the recrudescence of
malaria as a major killer in many developing countries.
Many questions remain, however. There is very little
information about the interactions of different genetic
modiﬁers, clear evidence that other modiﬁers remain to
be discovered, and at least a hint that the clinical phe-
notype of the thalassemias, which changes during differ-
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ent stages of development, may reﬂect innate variation in
the ability to adapt to severe anemia.
Population Genetics and Dynamics
Although J. B. S. Haldane originally suggested in 1949
that the high frequency of the thalassemias might reﬂect
heterozygote advantage against severe malaria (Haldane
1949), it is only recently that deﬁnite evidence has been
obtained that his hypothesis was correct. It has been
found that, in the case of the milder forms of a thal-
assemia, homozygotes—that is, those with two out of
four a genes (a/a)—and probably heterozygotes
(a/aa) are resistant to the complications of Plasmo-
dium falciparum malaria. Remarkably—at least in Papua
New Guinea, where these studies were carried out—
those with a thalassemia are also more resistant to other
childhood infections, notably upper-respiratory-tract in-
fection (Allen et al. 1997). Whether this is mediated
through their better overall health due to protection
against the debilitating effects of chronic malaria or
whether it is due to a more direct effect of a thalassemia
on their immune status remains to be determined. But
whatever the mechanism, it is clear that the a thalas-
semias are having a major effect on the overall health of
children in highly malarious regions. Although the ap-
propriate case-control studies have not yet been com-
pleted, there is strong circumstantial evidence that the
high frequencies of b thalassemia and Hb E may also
reﬂect heterozygote resistance to malaria.
Since it is now clear that many genetic polymorphisms
other than those involving hemoglobin have been main-
tained by differential susceptibility to malaria (Weather-
all and Clegg 2002), and because, in evolutionary terms,
human exposure to malaria is fairly recent, it follows
that patients with thalassemia from different parts of the
world are likely to have different genetic constitutions
with regard to susceptibility to malaria and a wide range
of other infectious organisms. Further work in this ﬁeld
should tell us a great deal about how natural protection
against malaria is mediated, to what extent genetic re-
sistance needs to be taken into account in the evaluation
of potential malaria vaccines, and some of the reasons
for the wide range and patterns of susceptibility to in-
fection that are shown by patients with severe forms of
thalassemia, a phenomenon that has never been ade-
quately explained. In view of the recrudescence of ma-
laria as a major health problem in many countries, these
questions are likely to be of importance for some time
to come.
Clinical Management
Although the introduction of bone-marrow trans-
plantation has offered the possibility of curing severe
forms of thalassemia, particularly if carried out early in
life, this is available only to a relatively small number
of patients in the developed countries and to an even
smaller fraction of those in the developing world. The
position will only be improved if the methods become
available for bone-marrow transplantation between non-
matching individuals or with the development of so-
matic-cell gene therapy. Both these developments may
take a long time to come to fruition and will probably
be extremely expensive. It is equally important, there-
fore, to continue research into better methods for ele-
vating Hb F levels, particularly in the case of interme-
diate forms of b thalassemia, which may be improved
very considerably by a small incremental rise in the steady-
state hemoglobin level (Olivieri et al. 1997).
However, regular treatment with blood transfusion
and iron-chelating agents, if pursued vigorously, is al-
lowing children with serious forms of b thalassemia to
survive into adult life in good health. The major prob-
lems to be resolved are the delivery of this type of care
to the poorer countries of the world, difﬁculties with
compliance, and, in particular, the lack of an oral che-
lating agent of proven effectiveness.
Population Control
It is still not widely appreciated that the thalassemias
are posing an increasingly serious health burden inmany
parts of the world, particularly the countries of Asia.
For example, it has been assessed recently that there are
between half and three quarters of a million severely
affected children in Thailand (World Health Organiza-
tion [WHO] 2002) and that the gene frequency in In-
donesia is such that to treat even a proportion of patients
in the future will require between 1.25 and 1.5 million
units of blood each year (de Silva et al. 2000). The major
challenge for the developing countries is, therefore, to
evolve programs for the population control of the thal-
assemias. This requires widespread public education, the
development of screening and counseling programs, the
establishment of at least one or two central laboratories
for the more deﬁnitive diagnosis of these conditions,
training clinicians to develop expertise in management,
and a decision on the part of the population as to
whether it wishes to develop prenatal diagnosis pro-
grams. Considering the extensive cultural and religious
differences in attitude to prenatal diagnosis, the latter
approach to population control requires a major effort
at education and long discussions between the com-
munities and well-informed doctors.
While there are many excellent examples of national
thalassemia-control programs, notably those in Cyprus
and Sardinia (Cao 1994; Angastiniotis andModell 1998),
many problems remain. In some countries, there are cul-
tural or religious objections to the termination of preg-
nancy, although the views are slowly changing. These
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programs should not be introduced quickly into societies
where there are considerable doubts about the ethical
issues involved. Rather, there should be adequate edu-
cation programs and counseling facilities available and
the population should, by a gradual process of debate
and social evolution, decide whether they wish to move
toward the type of control programs that have been so
successful in the Mediterranean countries. Currently, a
number of countries in the developing world are moving
in this direction. However, because control programs of
this type are undoubtedly cost effective compared with
the lifelong management of a large number of thalas-
semic patients, there may be a tendency for pressures to
be put on populations to evolve programs of this type.
It is vital that this type of coercion be avoided.
Thus, while many problems remain, it should be pos-
sible, by the establishment of North-South partnerships
and local networks, to evolve programs for the better
control and care of thalassemia in the future (WHO
2002).
The Contribution of the Thalassemia Field
to an Understanding of Genetic and Acquired
Disorders Unrelated to Hemoglobin
As well as providing the ﬁrst hint as to the likely rep-
ertoire of mutations that underlie monogenic disease and
proof of principle that disease loci may be traced by
their linkage to restriction fragment-length polymor-
phisms (Kan and Dozy 1978), the hemoglobin ﬁeld has
contributed toward an understanding of a number of
nonhemoglobin disorders.
a Thalassemia and Mental Retardation
When we ﬁrst encountered threeNorth European fami-
lies with Hb H disease—a moderately severe form of a
thalassemia—and mental retardation, it was not clear
whether this was a chance association or whether the
two conditions shared a common etiology (Weatherall
et al. 1981). Because of the unusual pattern of inheri-
tance and because a thalassemia is rare in individuals
of European origin, it was suggested that the two con-
ditions might be connected and that an understanding
of the molecular basis of this unusual form of a thal-
assemia might shed some light on the reasons for the
associated mental retardation. After the ﬁrst publication
stimulated others to search for this association, it gradu-
ally became apparent that there are two speciﬁc syn-
dromes associated with a thalassemia and mental retar-
dation, which are encoded on chromosome 16 (ATR-16)
and on the X chromosome (ATR-X), respectively (Wilkie
et al. 1990a, 1990b; Higgs, 2001).
ATR-16, which is usually associated withmild-to-mod-
erate mental retardation without any particular pattern
of associated developmental abnormalities, is caused by
subtelomeric deletions or chromosomal rearrangements
of the short arm of chromosome 16 that involve the a
globin–gene cluster and a number of other deﬁned loci.
These ﬁndings suggested that submicroscopic, subtelom-
eric deletions might be the basis for a signiﬁcant number
of hitherto-unexplained cases of mental retardation; sub-
sequent studies conﬁrmed that this is the case (Flint et
al. 1995).
ATR-X is characterized by relatively severe mental re-
tardation, characteristic facial deformities, skeletal ab-
normalities, and, in some cases, abnormal genitalia. The
gene that is involved, ATRX, located at Xq13.3, encodes
a member of the SW12/SNF2 family of helicases (Gib-
bons et al. 1995, 1997). Like other proteins of this type,
ATRX has—in addition to a PHD region—a DNA-bind-
ing region and an ATPase/helicase domain, reﬂecting its
ATP-dependent nucleosome-remodeling and DNA-
translocase activities. The ATRX protein is associated
with the nuclear matrix during interphase (McDowell
et al. 1999) and with condensed chromatin and shows
interactions with HP1 and EZH2, heterochromatin-
binding proteins. Its probable role is related to acces-
sibility of various DNAmethyltransferases to chromatin;
patients with ATRX show defective methylation of rDNA
and other repetitive sequences (Gibbons et al. 2000).
They have a very mild form of a thalassemia that is
sometimes characterized by a small proportion of cells
with Hb H inclusions; similar ﬁndings, though even
milder, can often be identiﬁed in female carriers.
ATR-X, which has been shown to be involved in a
number of other X-linked syndromes associated with
mental retardation (Ausio´ et al. 2003), is therefore the
ﬁrst of a growing list of syndromes characterized by dis-
ordered chromatin remodeling.
a Thalassemia and Myelodysplasia
The association of a form of a thalassemia with a
myelodysplastic syndrome in elderly patients has been
recognized for many years. Early work suggested that
there might be a complete absence of a-chain production
in the affected cell lines in this disorder (Weatherall et
al. 1978). Until recently, it was difﬁcult to isolate the
appropriate cell populations to examine the molecular
pathology of this condition. However, recent work util-
izing microarray analyses has shown that this condition
results from somatic mutations of ATRX (Gibbons et al.
2003). These studies provide clear evidence that null
mutations of ATRX are associated with a profound de-
fect in a-globin production, indicating that the ATRX
protein plays an essential role in a chain synthesis. These
ﬁndings are compatible with the observation that Atrx
knockout embryos in mice that express no full-length
proteins do not develop beyond 9 days. It appears, there-
390 Am. J. Hum. Genet. 74:385–392, 2004
fore, that constitutional null mutations of ATRX are
lethal, while somatic mutations that involve the hema-
topoietic cell line may be associated with neoplastic
transformation of the bone-marrow progenitors. The
mechanisms for the latter changes, and whether other
genes are involved, remain to be determined.
b Thalassemia and Trichothiodystrophy
Recently, it has been found that the mutations in XPD
that cause trichothiodystrophy (TTD) are frequently as-
sociated with a reduced expression of the b-globin genes
and with the clinical phenotype of heterozygosity for b
thalassemia (Viprakasit et al. 2001). The XPD protein
is a subunit of the basal transcription factor, TFIIH. As
well as the phenotype of b thalassemia trait, these pa-
tients have reduced levels of b-globin synthesis and b-
globin mRNA. The transcription factor TFIIH is in-
volved in both basal transcription and DNA repair.
These observations provide the ﬁrst evidence for reduced
expression of a speciﬁc gene in TTD and support the
concept that many of the clinical features of this con-
dition result from inadequate expression of a diverse set
of highly suppressed genes.
Lessons for the Future
By analyzing the molecular basis of unusual thalas-
semia phenotypes, considerable light has been shed on
the pathogenesis of some forms of mental retardation
associated with dysmorphological features and on other
complex syndromes. These ﬁndings illustrate the im-
portance of the detailed exploration of cases in which
unusual phenotypes appear to be associated with com-
mon genetic disorders. It is quite possible that other de-
velopmental disorders result from mutations in genes for
ubiquitous regulatory proteins, some of which may also
be involved with globin-chain synthesis. Detailed mor-
phological studies of the blood are, therefore, well
worthwhile pursuing in any patient with unexplained
syndromes of this type; ATRX was missed for many
years simply because there seemed to be no reason for
carrying out careful hematological analysis in patients
with mental retardation.
Conclusions
A great deal is known about the molecular pathology
of the thalassemias and about the genetic factors that
modify their phenotypes. Like for most monogenic dis-
eases, the role of the environment in phenotypic varia-
bility has been neglected, although there is increasing
evidence that this may be of major importance. The cen-
tral problem now is how to transport the practical ap-
plications of all this information for the beneﬁt of pa-
tients in countries with particularly high frequencies of
these conditions, notably those of Asia.
The deﬁnition of the different syndromes of a and b
thalassemia associated with genetic diseases that do not,
at ﬁrst sight, appear to be associated with any hema-
tological abnormalities is also of considerable impor-
tance, offering, as it does, the possibility of obtaining
insights into the etiology of these conditions. Hence, the
thalassemia ﬁeld, as well as its great importance tomany
populations in the developing countries, will continue
to provide valuable information for clinical genetics in
general.
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